in eleven patients (eGFR 60 ± 6 ml/min) during elective diagnostic cardiac catheterizations. In these 31 patients FGF-23 was removed by the kidney, with a fractional extraction (FE) of ~22%. The FE of 32 FGF-23 across the kidney was similar to that of creatinine (~17 %, p=NS). In addition, the FGF-23 33 FE by the kidney was significantly directly related to eGFR (r = 0.709 p = 0.018) and to kidney 34 creatinine FE (r=0.736 p=0.013) but only as a trend, to plasma phosphate levels (r=0.55, p=0.18).
Introduction

45
Fibroblast Growth Factor-23 (FGF-23) is a 32-kDa glycoprotein, bone-derived hormone 46 which circulates as an active full-length protein and shorter, inactive fragments (1, 26, 28) . Intact In this study, to provide a better understanding of sites and mechanisms which regulate procedures were in accordance with the Helsinki declaration.
111
The patients were studied in the postabsorptive state. Three sets of blood samples were obtained at 
116
Blood samples were collected in cooled ethylenediaminetetraacetate tubes added with aprotinin, 117 which were immediately centrifuged at 6000 rpm for 10 min at +4 °C. Plasma was quickly separated from 118 blood cells and stored at −80° C until assayed. Plasma intact FGF-23 levels were determined using an ELISA 119 assay (Endo Millipore, Darmstadt, Germany) according to the manufacturer's protocol. This assay 120 measures intact FGF-23 by utilising a two-step format, since it employs a polyclonal goat anti-
121
FGF23 capture antibody and biotinylated polyclonal goat anti-FGF23 antibody to which 122 streptavidin-horseradish peroxidase (HRP) conjugate is added. Antibody epitope mapping data are 123 not currently available. For this assay the reported limit of sensitivity is 3.5 pg/ml, and the reported 124 appropriate range from 9.9 pg/ml to 2400 pg/ml. In our laboratory, the lowest limit of detection was 4 minimize variability, samples arterial and venous blood were all run in triplicate. All samples from one 127 individual were always run in the same batch. Blood pH, pO2, pCO 2 , glucose, lactate and creatinine were 128 measured with an ABL800 Flex apparatus (Radiometer, Copenhagen, Denmark). 129
130
Calculations and statistical methods
131
The A-V difference of FGF-23 across the splanchnic organs, kidney and heart/lung was calculated 
Results
142
Handling of FGF-23 by the kidney, splanchnic organs and cardiopulmonary bed 143 Individual arterial and venous levels of FGF-23, as well as its arterial-venous differences 144 across the kidney, splanchnic organs and cardiopulmonary bed are reported in Table 1 
DISCUSSION
161
The aim of this study was to learn more about the sites and mechanisms which regulate Figure 1A ), it appears that the renal 180 FGF-23 FE drops from ~45% to values close to zero when eGFR declines from ∼90 to ∼30 ml/min.
181
As a matter of fact the FGF-23 FE is even greater (ratio ∼2) than creatinine FE when eGFR is ∼90 182 ml/min, but declines steeply along with the decrease in eGFR ( Figure 1B) . Therefore, our data are 
212
In this study, we were not able to demonstrate a net removal of FGF-23 by splanchnic 
Disclosures
255
There is no information to disclose. Data are mean ± SEM. Abbreviations: BMI= Body Mass Index, GFR= Glomerular Filtration Rate. are the concentrations of metabolites in arterial and venous plasma. As for the cardio-pulmonary circulation, the differences were calculated as (V-A) Pulmonary Artery-Arterial systemic differences. A positive sign means uptake, while a negative sign means release. FE= fractional extraction;
